In addition, among non-small cell lung cancer patients, KEAP1 and STK11 mutated patients are not sensitive to immunotherapy and have shorter disease-free and overall survival17,18 (Fig. 4). This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.